Bioadaptives, Inc.

As of June 30, 2026, Bioadaptives, Inc. carries a market capitalization of 34,825.11, placing it among publicly traded companies globally. Its enterprise value stands at 528,467.11, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Bioadaptives, Inc. has 12.01M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.37, and the price-to-book ratio stands at -0.02.

These figures are as of June 30, 2026. The EV/Sales ratio of 20.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 528,467.11 versus a market cap of 34,825.11, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bioadaptives, Inc. maintains a current ratio of 0.04, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -29.60, indicating conservative leverage, while an interest coverage ratio of -3.55 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -662.63, reflecting losses generated across the asset base. The company generates approximately 25,561.00 in revenue per employee across its workforce of 1.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.15 indicates how many times Bioadaptives, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Bioadaptives, Inc.'s stock has declined approximately 94.27% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended June 30, 2026, Bioadaptives, Inc. generated 25,561.00 in revenue and converted that into -1.16M in net income, yielding earnings per share of -0.10. EBITDA reached -903,200.00, while operating income came in at -909,200.00.

As of June 30, 2026, Bioadaptives, Inc. holds 29,221.00 in cash and equivalents against 522,725.00 in total debt, resulting in a net debt position of 493,504.00. Total book value stands at -1.77M, with working capital of -1.78M providing operational flexibility.

Bioadaptives, Inc. produced -436,361.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -436,361.00 - equivalent to -0.04 per share.

Over the twelve months ended June 30, 2026, Bioadaptives, Inc. posted a gross margin of 77.41, reflecting its pricing power and cost economics. The operating margin of -3,556.98 and net profit margin of -4,553.20 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1,242.28: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

Bioadaptives, Inc.'s most recent stock split took place on January 23, 2025 with a 1:2 split ratio.

As of June 30, 2026, Bioadaptives, Inc. has an Altman Z-Score of -254.69, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.